2018.02.16. Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego

Written By Adam Parks

Abstract entitled "Antitumor efficacy following oral INV-25 Liver X receptor (LXR) agonist monotherapy in the B16-F10 melanoma mouse model" presented as Oral Poster Presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California February 16-20, 2018.

Read Here +

Adam Parks https://apollocreativeco.com
Previous

2022.04.12. Innovimmune's first-in-class oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors to be presented at the 2022 American Association for Cancer Research Annual Meeting
Next

2017.09.13. Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland